{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:27:02Z","timestamp":1781533622524,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11096-024-01758-2","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T12:12:24Z","timestamp":1720699944000},"page":"1317-1326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti\u2011CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two\u00a0years"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9595-5982","authenticated-orcid":false,"given":"E.","family":"Pons-Fuster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lozano-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mart\u00edn-Balbuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lucas-R\u00f3denas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mancebo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"De Gorostiza-Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Gonz\u00e1lez-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"4","key":"1758_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/0333102410382794","volume":"31","author":"J Mat\u00edas-Guiu","year":"2011","unstructured":"Mat\u00edas-Guiu J, Porta-Etessam J, Mateos V, et al. One-year prevalence of migraine in Spain: a nationwide population-based survey. Cephalalgia. 2011;31(4):463\u201370. https:\/\/doi.org\/10.1177\/0333102410382794.","journal-title":"Cephalalgia"},{"issue":"11","key":"1758_CR2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):954\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1758_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine. J Headache Pain. 2020;21(1):76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5.","journal-title":"J Headache Pain"},{"issue":"1","key":"1758_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40001-022-00716-w","volume":"27","author":"H Sevivas","year":"2022","unstructured":"Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res. 2022;27(1):86. https:\/\/doi.org\/10.1186\/s40001-022-00716-w.","journal-title":"Eur J Med Res"},{"issue":"1","key":"1758_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain. 2022;23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"issue":"22","key":"1758_CR6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038.","journal-title":"N Engl J Med"},{"issue":"24","key":"1758_CR7","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine. Neurology. 2018;91(24):e2211\u201321. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"issue":"12","key":"1758_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/03331024221103509","volume":"42","author":"R Riesenberg","year":"2022","unstructured":"Riesenberg R, Gaul C, Stroud CE, et al. Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache. Cephalalgia. 2022;42(12):1225\u201335. https:\/\/doi.org\/10.1177\/03331024221103509.","journal-title":"Cephalalgia"},{"issue":"10210","key":"1758_CR9","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(19)32504-8.","journal-title":"Lancet"},{"issue":"7","key":"1758_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/ph14070700","volume":"14","author":"T Mavridis","year":"2021","unstructured":"Mavridis T, Deligianni C, Karagiorgis G, et al. Monoclonal antibodies targeting CGRP: from clinical studies to real-world evidence\u2014What do we know so far? Pharmaceuticals (Basel). 2021;14(7):700. https:\/\/doi.org\/10.3390\/ph14070700.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1758_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, et al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain. 2023;24(1):23. https:\/\/doi.org\/10.1186\/s10194-023-01556-7.","journal-title":"J Headache Pain"},{"issue":"9","key":"1758_CR12","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1007\/s10072-022-06254-x","volume":"43","author":"S Quintana","year":"2022","unstructured":"Quintana S, Russo M, Manzoni GC, et al. Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine. Neurol Sci. 2022;43(9):5757\u20138. https:\/\/doi.org\/10.1007\/s10072-022-06254-x.","journal-title":"Neurol Sci"},{"issue":"10","key":"1758_CR13","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, et al. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. 2021;268(10):3789\u201398. https:\/\/doi.org\/10.1007\/s00415-021-10523-8.","journal-title":"J Neurol"},{"issue":"2","key":"1758_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, et al. Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs. 2022;36(2):191\u2013202. https:\/\/doi.org\/10.1007\/s40263-021-00893-y.","journal-title":"CNS Drugs"},{"issue":"10","key":"1758_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache. 2020;60(10):2454\u201362. https:\/\/doi.org\/10.1111\/head.13956.","journal-title":"Headache"},{"issue":"1","key":"1758_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A, et al. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain. 2021;22(1):120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1.","journal-title":"J Headache Pain"},{"key":"1758_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231177636","author":"A Alpuente","year":"2023","unstructured":"Alpuente A, Torre-Sune A, Caronna E, et al. Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: a real-world evidence study. Cephalalgia. 2023. https:\/\/doi.org\/10.1177\/03331024231177636.","journal-title":"Cephalalgia"},{"issue":"33","key":"1758_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ane.13472","volume":"144","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, di Clemente S, et al. Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand. 2021;144(33):325\u201333. https:\/\/doi.org\/10.1111\/ane.13472.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1758_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32. https:\/\/doi.org\/10.1186\/s10194-020-01102-9.","journal-title":"J Headache Pain"},{"issue":"15","key":"1758_CR20","doi-asserted-by":"publisher","first-page":"11993","DOI":"10.3390\/ijms241511993","volume":"24","author":"N Karsan","year":"2023","unstructured":"Karsan N, Gosalia H, Goadsby PJ. Molecular mechanisms of migraine: nitric oxide synthase and neuropeptides. Int J Mol Sci. 2023;24(15):11993. https:\/\/doi.org\/10.3390\/ijms241511993.","journal-title":"Int J Mol Sci"},{"key":"1758_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01644-8","author":"A Labastida-Ram\u00edrez","year":"2023","unstructured":"Labastida-Ram\u00edrez A, Caronna E, Gollion C, et al. Mode and site of action of therapies targeting CGRP signaling. J Headache Pain. 2023. https:\/\/doi.org\/10.1186\/s10194-023-01644-8.","journal-title":"J Headache Pain"},{"issue":"2","key":"1758_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098614522683","volume":"5","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5(2):87\u201399. https:\/\/doi.org\/10.1177\/2042098614522683.","journal-title":"Ther Adv Drug Saf"},{"key":"1758_CR23","doi-asserted-by":"publisher","first-page":"1129439","DOI":"10.3389\/fneur.2023.1129439","volume":"14","author":"AV Krymchantowski","year":"2023","unstructured":"Krymchantowski AV, Jevoux C, Krymchantowski AG, et al. Monoclonal antibodies for chronic migraine and medication overuse headache: a real-world study. Front Neurol. 2023;14:1129439. https:\/\/doi.org\/10.3389\/fneur.2023.1129439.","journal-title":"Front Neurol"},{"issue":"1","key":"1758_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1.","journal-title":"J Headache Pain"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01758-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:07:45Z","timestamp":1732068465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01758-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1758"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01758-2","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}